Nov. 21, 2019, the U.S. Food and Drug Administration (FDA) - as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada - granted supplemental approval to acalabrutinib (Calquence ) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Calquence provides a new treatment option for patients with CLL or SLL as an initial or subsequent therapy.
Read FDA announcement.
Read AstraZeneca corporate press release.
Posted 11/21/2019
Re-posted 11/26/2019
